New research offers hope for treating MPNST
Author: Maddy Schmitt, WashU Medicine
Published On: 11/18/26
Dr. Angela Hirbe, MD, PhD, and her team published exciting new research in the Journal of Clinical Investigation that could lead to a new treatment approach for malignant peripheral nerve sheath tumors (MPNST), an aggressive type of cancer that can be difficult to treat.
The laboratory study, led by Dr. Guangfeng Wang, focused on a common genetic feature of MPNST: many of these tumors have an extra copy of chromosome 8. Because the gene that makes a protein called FAK is located on chromosome 8, having an extra copy can cause MPNST cells to produce unusually high levels of FAK. FAK helps cancer cells grow and behave more aggressively, and importantly, whether FAK can be blocked with an oral drug.
In laboratory models, blocking FAK alone was able to stop tumors from growing, but the tumors did not shrink. The researchers discovered that the cancer cells responded by increasing signaling through another pathway, called MEK, which allowed them to keep growing. When the researchers combined a FAK inhibitor with a MEK inhibitor, this resistance mechanism was overcome and the tumors shrank.
These findings have now moved from the laboratory toward clinical testing. Dr. Jerod Sears, a member of the Hirbe lab, and Dr. Vanessa Eulo, a former member of the lab, have developed a clinical trial to test this combination in patients with MPNST. The trial, NF120: Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumors, is expected to open in early 2027.
This work represents an important step toward translating a biological insight about MPNST into a potential new treatment strategy for patients with this challenging cancer.
Find upcoming NF Events Donate to NF Stay iNFormed
Want to view archived newsletters? Click Here!
Newsletter
Sign up to receive the latest neurofibromatosis news and information in your inbox!
Subscribe